SynerFuse has announced the appointment of Rohan Lall (M Health Fairview Neurosurgery, Princeton, USA) as the company’s chief medical officer. The appointment was effective on 2 January 2024.
“Dr Lall has been instrumental in SynerFuse progressing to where we are today,” said the company’s chief executive officer and co-founder Justin Zenanko. “We are thrilled that he has agreed to join our management team.”
Along with Michael Park (University of Minnesota, Minneapolis, USA), SynerFuse co-founder Greg Molnar, and Zenanko, Lall co-developed the patented electric transforaminal lumbar interbody fusion (e-TLIF) SynerFuse procedure, which combines fusion with direct nerve stimulation to treat chronic low back and leg pain that is unaddressed in traditional spinal fusion surgery.
Lall is a neurosurgeon specialising in robotic and minimally invasive spine surgery, complex spinal surgery, surgery for brain and spinal tumours, and skull base surgery/pituitary tumour surgery. He has been a leader in robotic spinal surgery and is actively involved in the development of new technologies in spine surgery, as per a SynerFuse press release.
“I’m thrilled to join the SynerFuse management team,” Lall said. “If the SynerFuse e-TLIF procedure proves effective at lowering postoperative pain levels, as early indications have suggested, we may have a new treatment strategy that potentially saves the healthcare system billions of dollars over time and improves pain management outcomes. That’s exciting.”
